To accommodate this limitation, we focused on using the cyst persistence factor CST1 and assessed the feasibility of enhanced cyst reduction since most of the T. gondii vaccine studies reported to date emphasized the use of host invasion factors as antigens. The gene discussed is CST1; the disease is cyst.